Concepedia
Statistics
Publications
1
Citations
54
H-Index
Active since
2023
Affiliations
Publications per year
2023–2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Komal Jhaveri, L.D. Eli, Hans Wildiers et al. · Annals of Oncology · 2023 · 54 citations · Full text
1–1 of 1